The SWI/SNF complex participates as a co-activator in the transcriptional regulation of certain genes. Conversely, we and others have recently established that Brg1 and Brm, the central components of SWI/SNF, act instead as co-repressors for E2F-mediated transcriptional repression, and for the transcription of certain other promoters. We report here that Brg-1 and Brm can switch their mode of function at same promoter between activation and repression by ligand-directed differential coordination with BAF155, BAF170, HDAC1, p300 and prohibitin. This ligand and context-dependent reprogramming of the SWI/SNF complex allows it to differentially serve as either a co-repressor or a co-activator of transcription at the same promoter.
Introduction
Alteration of nucleosome structure by ATP-dependent remodeling complexes is a critical step in transcriptional regulation (Muchardt and Yaniv, 1993; Dunaief et al., 1994; Peterson and Tamkun, 1995; Goodwin, 1997; Muchardt et al., 1998; DeCristofaro et al., 1999; Murphy et al., 1999; Yaniv, 1999, 2001; Dahiya et al., 2000; de la Serna et al., 2001; Betz et al., 2002; Reisman et al., 2002; Roy et al., 2002; Wang et al., 2002b Wang et al., , 2004 Dasgupta et al., 2004; Roche et al., 2004; Inayoshi et al., 2006) . The molecular mechanism responsible for these divergent functions of the SWI/ SNF complex has not been fully defined.
We recently found that prohibitin (20-26), a potential tumor suppressor and its co-repressors, Brg1 and Brm, are required for estrogen antagonist-induced growth suppression, which is estrogen receptor (ER) dependent . It has been reported that ER-mediated transcriptional activation by estrogen also requires Brg1 (DiRenzo et al., 2000; Wang et al., 2002b Wang et al., , 2004 and we show in this report that Brm is required. This finding of a requirement for Brm and Brg1 for both ligand-dependent transcriptional activation and for repression of the same set of genes enabled us to use ER-responsive transcription machinery as a model to investigate the divergent roles of SWI/ SNF in transcriptional regulation. We report here that Brg1 and Brm are required for repression of ERmediated transcription, demonstrating that the same chromatin remodeling molecules, Brg1/Brm, play active roles in both activation and repression of the same promoters.
The human SWI/SNF chromatin-remodeling complex contains factors in addition to Brm and Brg1, named BAFs (Brg1-associated factors). The molecular mechanisms of the transcriptional regulation by BAFs are not fully elucidated (Wang et al., 1996a, b; Lee et al., 1999; Decristofaro et al., 2001; Chi et al., 2002 Chi et al., , 2003 Fukuoka et al., 2004; Chen and Archer, 2005; Zhao et al., 2005; Foster et al., 2006) . Acetylation and deacetylation of histones also contribute to transcriptional regulation, presumably through chromatin remodeling (Ferreira et al., 2001; Morrison et al., 2002; Boutillier et al., 2003; Gunawardena et al., 2004; Banchio et al., 2006) , and can be modulated by the recruitment of histone deacetylases (HDAC) and histone acetylases, such as p300 (Hanstein et al., 1996; Wang et al., 1996a, b; Brehm et al., 1998 Brehm et al., , 1999a Luo et al., 1998; Magnaghi-Jaulin et al., 1998; Brehm and Kouzarides, 1999; Luo and Dean, 1999; Panteleeva et al., 2004) .
In this study, we report that Brg1/Brm, BAF155 and BAF170 are differentially recruited to the same ERresponsive promoters, but through different proteins, in response to growth-promoting hormones (estrogen) or growth-suppressing agents (estrogen antagonists). Two functionally divergent consequences of differential recruitment of BAF155 and BAF170 to the same promoter are the subsequent recruitment of the coactivator histone acetylase p300, or instead of the co-repressor HDAC1. Complexes containing Brm/Brg1 and BAFs thereby mediate ER-responsive gene transcriptional activation when recruited by an estrogenliganded ER, but mediate suppression when recruited through the prohibitin tumor suppressor by an estrogen antagonist-liganded ER.
Results
Brg1 and Brm are required for transcriptional repression of ER-driven genes by estrogen antagonists It has been reported that Brg1 is involved in ERmediated transcriptional activation (DiRenzo et al., 2000; Belandia et al., 2002; Matsuda et al., 2002) . We recently established that a tumor suppressor, prohibitin, and its co-repressors Brg1 and Brm, are required for estrogen antagonist-induced growth suppression (Wang et al., 2002b . We therefore tested whether Brg1 and Brm also participate in ER-mediated transcriptional repression. The ER-responsive ERE-Luc reporter was transfected into MCF7 cells, with or without small interfering RNA (siRNA) specific for Brg-1 or Brm. When Brg1 or Brm was depleted from the cells by the expression of siRNA, the suppressive effect of estrogen antagonists on ER-mediated transcription was abrogated, indicating that Brg1 and Brm are required for ER-mediated transcriptional repression ( Figure 1 ). Interestingly, over-expression of prohibitin also repressed estrogen-induced ERE-luc activity, and this repression was also abrogated when Brg1 or Brm were depleted by siRNA. Transfection of control SiRNA did not affect the repressive effects of estrogen antagonists or prohibitin ( Figure 1) .
We have previously reported that the recruitments of Brg1/Brm to E2F-responsive promoters were mediated by prohibitin. We therefore tested the necessity of prohibitin in the recruitment of Brg1 and Brm to ERresponsive promoters in response to estrogen and its antagonists and found that prohibitin can associate with ER-responsive promoter and prohibitin is required for the Brg1 and Brm recruitment in response to estrogen antagonists (see Supplementary Figure S1 ).
Associated components of the SWI/SNF complex are differentially recruited for activation versus suppression of ER transcriptional activity The SWI/SNF complex contains various BAFs in addition to Brg1 and Brm. BAF155, one core component of this chromatin-remodeling complex, contributes to the transcriptional activation of nuclear hormone receptor GR by SWI/SNF (Fryer and Archer, 1998) . Interestingly, BAF155 has also been found to be involved in E2F-mediated transcriptional repression via cyclin E (Shanahan et al., 1999) . We therefore tested whether BAF155, and BAF170, another component of the core human SWI/SNF, are critically and differentially involved in the regulation of ER-mediated transcription. A chromatin immunoprecipitation assays (ChIP) assay was performed using MCF7 cells treated with ethanol (vehicle control), estrogen or estrogen antagonists. Treatment of MCF7 cells with estrogen induced the expected transcriptional activation of the pS2 promoter, as demonstrated by reverse transcription-polymerase chain reaction (RT-PCR) and ChIP of Pol II (Figure 2a ). Estrogen also induced recruitment of both BAF155 and BAF170 to the promoter, suggesting their involvement in estrogen-mediated transcriptional activation. In contrast, estrogen antagonists, 4HT (shown) and ICI 182780 (not shown), induced the recruitment of BAF155, but not BAF170, to the pS2 promoter, indicating that BAF170 may not be required for estrogen antagonist-induced transcriptional repression. To verify this possibility, we repeated the ChIP experiments using MCF7 cells in which either BAF155 or BAF170 had been depleted by siRNA (Figure 2b) . Depletion of BAF155 blocks the ability of both estrogen and its antagonists to differentially regulate the pS2 promoter, as shown by CHIP of Pol II and RT-PCR. 
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However, whereas estrogen failed to induce pS2 promoter activity in the absence of BAF170, estrogen antagonists (4HT shown, ICI182780 not shown) effectively repressed the pS2 promoter, indicating that BAF170 is required in the SWI/SNF co-regulatory complex which mediates estrogen-induced transcriptional activation, but not in the SWI/SNF complex which mediates estrogen antagonist-induced transcriptional repression. We and others have recently established that histone acetylation status and acetylation modulating proteins (p300, HDAC1, and so on) are associated with E2F-mediated transcriptional regulation (Brehm et al., 1998 (Brehm et al., , 1999a Brehm and Kouzarides, 1999; Morris et al., 2000; Wang et al., 2002a) . p300 and HDAC1 have also been reported to play critical roles in regulation of ERmediated transcriptional activity (Hanstein et al., 1996; Margueron et al., 2004; Jeffy et al., 2005; Lin et al., 2005) . Interestingly, it has been recently reported that Brg1 collaborates with histone acetylation modulators in regulating ER-mediated transcription. We therefore tested whether the loss of regulation of ER-mediated transcriptional activity by estrogen or its antagonists in the absence of BAF155 or BAF170 is related to recruitment of modulators of histone acetylation. As shown in Figure 2a , the association of the histone acetylase co-activator p300 with the pS2 promoter in MCF7 cells was induced by estrogen but not by its antagonists, while the recruitment of the HDAC corepressor HDAC1 was induced only by estrogen antagonists (4HT shown). Interestingly, in the absence of BAF155, there was no detectable basal or ligandinduced association of either HDAC1 or p300 with the pS2 promoter, and no effect of either antagonist or estrogen on promoter transcriptional activity, indicating that BAF155 is necessary for the recruitment of both HDAC1 and of p300, and for differential regulation of transcription by ER ligands. In contrast, antagonistinduced recruitment of HDAC1, and the coincident repression of the pS2 promoter, was not affected by the absence of BAF170, indicating that BAF170 is required only for p300 recruitment and ER-mediated transcriptional activation by estrogen, but not for HDAC1 recruitment and repression of ER-mediated transcription by estrogen antagonists. Thus, the same chromatinremodeling molecules, Brg1/Brm, participate in both transcriptional repression and activation on the same promoter, through ligand-specific differential collaboration with, and recruitment of, BAFs, HDAC1, p300 and prohibitin.
Discussion
Major cell cycle events are modulated via transcriptional regulation of growth-promoting and repressing genes. Despite major advances in the study of transcriptional control, however, the molecular mechanisms responsible for switching the modes of promoter activities between activation and repression are not fully elucidated. Our discovery that the same gene (in this case pS2) utilizes the SWI/SNF complex for both transcriptional activation and repression has allowed us to investigate how these divergent outcomes can be generated by the same core ATPase complex (further discussed in Supplementary Materials online).
Materials and methods

Cell culture, vectors and transfections
The details of these techniques have been previously described in detail . Briefly, cells were maintained in Dulbecco's modified Eagle medium (MCF7 and T47D), or DME (MDA-MB-231) containing 10% fetal bovine serum. A total of 2 mg of plasmid vectors was used in all transfections for reporter analyses, unless otherwise noted. One microgram of a pSV-bGal vector was included as internal control in all transfections. In all cases, luciferase assays were repeated at least three times, using standard protocols, and the averages of Figure 2 BAFs (Brg1-associated factors), HDAC1 (histone deacetylases 1) and p300 are differentially recruited during reprogramming of estrogen receptor-mediated transcription. Cells were treated with the indicated reagents at established concentrations reported previously . Cell extracts of MCF7 and MCF7 cells transfected with BAF155 or BAF170 siRNA were analysed by ChIP assay using the indicated antibodies (a). The suppression of BAF protein levels by siRNA expression was verified by immunoblotting (b). 4-HT: 4-hydroxy-tamoxifen.
Regulation of ER by Brg1, Brm and prohibitin B Zhang et al the results are shown with standard deviations. The total amount of DNA used in each transfection was normalized with salmon sperm DNA. The ERE-Luc reporter was a gift from Dr Junn Yanagisawa at University Tsukuba (Fujita et al., 2003) . HA-tagged deletions of prohibitin were generated by PCR and cloned into pCRA3.1. The HA-tagged ERbinding domain of prohibitin was commercially synthesized and cloned into pCDNA3.1 (GenScript Corporation, Piscataway, NJ, USA). SiRNA for prohibitin, Brg1 and Brm, stable transfection protocols, and estrogen/antagonists were described previously (Wang et al., 2002b . BAF170 siRNA (h) (Cat # sc-29782) and BAF155 siRNA (h) (sc-29780) were purchased from Santa Cruz (Santa Cruz, CA, USA). Transfections of the BAF siRNAs were performed according to the protocol provided by the supplier.
Immunoprecipitation and immunoblotting protocols These were described previously (Wang et al., 2002b . All antibodies were purchased from Santa Cruz except the anti-prohibitin antibody, which was purchased from NeoMarkers (Fremont, CA, USA) (via Lab Vision Corporation, Fremont, CA, USA).
ChIP
ChIP assays were carried out as we have established previously, using the primers we reported .
